Axsome Therapeutic Inc will present data on Sunosi (solriamfetol), including results from the SHARP study, at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30 to June 3 in Miami.
According to the company, Sunosi is demonstrating improvement in cognitive function in patients with excessive daytime sleepiness associated with obstructive sleep apnea.
Details for the upcoming ASCP presentations are as follows:
Effects of Solriamfetol on Cognitive Function in Participants with Cognitive Impairment Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea: Results of the Sharp Study
Poster Session: Salon 4
Lead Author: Eileen Leary, PhD, Axsome Therapeutics
Date/Time: Wednesday, May 31, from 11:15 am – 1 pm ET
Excessive Daytime Sleepiness in a Real-World Study of Participants with Obstructive Sleep Apnea with or without Comorbid Depression
Poster Session: Salon 4
Lead Author: Samantha Floam, DMD, Axsome Therapeutics
Date/Time: Thursday, June 1, from 12:30 pm – 2:15 pm ET
Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion
Poster Session: Salon 4
Lead Author: Gregory Parks, PhD, Axsome Therapeutics
Date/Time: Thursday, June 1, from 12:30 pm – 2:15 pm ET
Sunosi received US Food and Drug Administration approval on March 20, 2019, to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Sunosi has orphan drug designation for narcolepsy in the United States.
